Some of our cancer centers are experiencing issues.  View More Important Notifications x
texas oncology more breakthroughs. more victories



Kristi McIntyre, M.D.

Kristi McIntyre, M.D.

Provider Type: Physician

  • Hematology
  • Medical Oncology
Board Certifications:
  • Medical Oncology
  • Internal Medicine

General Summary

Kristi J. McIntyre, M.D. serves on the Breast Cancers Committee for The US Oncology Network and on the Pharmacy and Therapeutics Committee and Nursing and Allied Health Scholarship Committee for Presbyterian Hospital. Dr. McIntyre is Principal Investigator for US Oncology Research Network at Dallas Presbyterian Clinic.


Medical degree in 1982 from Tulane University School of Medicine, New Orleans, Louisiana; internship and residency in Internal Medicine and Medical Oncology at University of Mississippi School of Medicine, Jackson, Mississippi 1982-1985; internal medicine fellowship at University of Mississippi School of Medicine 1986-1988; oncology/hematology fellowship at Mayo Medical School, Rochester, Minnesota 1988-1989.


  • Results of a Phase III trial doxoroubicin/cyclophosphamide (AC) compared to docetaxel/cyclophosphamide (TC) as adjuvant therapy for operable breast cancer.

    Journal of Clinical Oncology, 2006

  • Are granulocyte colony-stimulating growth factors (CSF’s) needed to prevent febrile neutropenia (FN) for course #1 of adjuvant chemotherapy with “standard” doxorubicin-cyclophosphamide (ASC) Results from two consecutive US Oncology community adjuvant trials.

    Breast Cancer Research and Treatment, 2006

  • Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer. 

    Journal of Clinical Oncology, 2006

Accolades & Memberships

American Medical Association and American College of Physicians and American Society of Clinical Oncologists. In 2009 D Magazine elected Dr. McIntyre as one of the best hematology oncologists in Dallas, Texas.